Abstract：
Drug coupons are widely used, but their effects are not well understood.
To quantify the effect of coupons on statin use and expenditures.
Retrospective cohort analysis of IMS Health LRx LifeLink database.
U.S. retail pharmacy transactions.
Incident statin users who initiated branded atorvastatin or rosuvastatin between June 2006 and February 2013.
Monthly statin utilization (pill-days of therapy), switching (filling a different statin), termination (failure to refill statin for 6 mo), and out-of-pocket and total costs.
Of 1.1 million incident atorvastatin and rosuvastatin users, 2% used a coupon for at least one statin fill. At 1 year, compared with noncoupon users, those who used a statin coupon on their first fill were dispensed an equal number of monthly pill-days (23.7 vs 23.8), were less likely to switch statins (14.4% vs 16.3%), and were less likely to have terminated statin therapy (31.3% vs 39.2%). At 4 years, coupon users were more likely to have switched (45.5% vs 40.8%) and less likely to have terminated statin therapy (50.6% vs 61.1%) compared with noncoupon users. Those who used greater numbers of coupons were substantially less likely to switch and terminate statin therapies. Monthly out-of-pocket costs were lower among coupon than noncoupon users at 1 year ($9.7 vs $15.1), but total monthly costs were qualitatively similar ($115.5 vs $116.9). At 4 years, monthly out-of-pocket costs among coupon users remained lower ($14.3 vs $16.6) compared with noncoupon users. Sensitivity analyses supported the main results.
Coupons for branded statins are associated with higher utilization and lower rates of discontinuation and short-term switching to other statin products.
To quantify the effect of coupons on statin use and expenditures.
Retrospective cohort analysis of IMS Health LRx LifeLink database.
U.S. retail pharmacy transactions.
Incident statin users who initiated branded atorvastatin or rosuvastatin between June 2006 and February 2013.
Monthly statin utilization (pill-days of therapy), switching (filling a different statin), termination (failure to refill statin for 6 mo), and out-of-pocket and total costs.
Of 1.1 million incident atorvastatin and rosuvastatin users, 2% used a coupon for at least one statin fill. At 1 year, compared with noncoupon users, those who used a statin coupon on their first fill were dispensed an equal number of monthly pill-days (23.7 vs 23.8), were less likely to switch statins (14.4% vs 16.3%), and were less likely to have terminated statin therapy (31.3% vs 39.2%). At 4 years, coupon users were more likely to have switched (45.5% vs 40.8%) and less likely to have terminated statin therapy (50.6% vs 61.1%) compared with noncoupon users. Those who used greater numbers of coupons were substantially less likely to switch and terminate statin therapies. Monthly out-of-pocket costs were lower among coupon than noncoupon users at 1 year ($9.7 vs $15.1), but total monthly costs were qualitatively similar ($115.5 vs $116.9). At 4 years, monthly out-of-pocket costs among coupon users remained lower ($14.3 vs $16.6) compared with noncoupon users. Sensitivity analyses supported the main results.
Coupons for branded statins are associated with higher utilization and lower rates of discontinuation and short-term switching to other statin products.
摘要：
药物券被广泛使用，但是它们的影响还没有得到很好的理解。
量化优惠券对他汀类药物使用和支出的影响。
IMSHealthLRxLifeLink数据库的回顾性队列分析。
美国零售药房交易。
2006年6月至2013年2月期间使用品牌阿托伐他汀或瑞舒伐他汀的事件他汀类药物使用者。
每月他汀类药物使用率（治疗的药丸天数），转换（填充不同的他汀类药物），终止（未补充他汀类药物6个月），以及自付费用和总成本。
在110万阿托伐他汀和瑞舒伐他汀使用者中，2%的人使用优惠券进行至少一次他汀类药物填充。在1年,与非优惠券用户相比，那些在第一次填充时使用他汀类药物优惠券的人被分配了相等数量的每月服药天数(23.7对23.8)，更换他汀类药物的可能性较小（14.4%vs16.3%），并且不太可能终止他汀类药物治疗(31.3%vs39.2%).四年后，与非优惠券用户相比,优惠券用户更有可能切换(45.5%vs40.8%),终止他汀类药物治疗的可能性较小(50.6%vs61.1%).那些使用更多数量的试样的人基本上不太可能改变和终止他汀类药物治疗。在1年时，优惠券用户的每月自付费用低于非优惠券用户（9.7美元对15.1美元），但每月总费用在质量上相似(115.5美元对116.9美元)。四年后，与非优惠券用户相比，优惠券用户的每月自付费用仍然较低(14.3美元对16.6美元)。敏感性分析支持主要结果。
品牌他汀类药物的优惠券与更高的利用率和更低的停药率以及短期转换为其他他汀类药物产品相关。
量化优惠券对他汀类药物使用和支出的影响。
IMSHealthLRxLifeLink数据库的回顾性队列分析。
美国零售药房交易。
2006年6月至2013年2月期间使用品牌阿托伐他汀或瑞舒伐他汀的事件他汀类药物使用者。
每月他汀类药物使用率（治疗的药丸天数），转换（填充不同的他汀类药物），终止（未补充他汀类药物6个月），以及自付费用和总成本。
在110万阿托伐他汀和瑞舒伐他汀使用者中，2%的人使用优惠券进行至少一次他汀类药物填充。在1年,与非优惠券用户相比，那些在第一次填充时使用他汀类药物优惠券的人被分配了相等数量的每月服药天数(23.7对23.8)，更换他汀类药物的可能性较小（14.4%vs16.3%），并且不太可能终止他汀类药物治疗(31.3%vs39.2%).四年后，与非优惠券用户相比,优惠券用户更有可能切换(45.5%vs40.8%),终止他汀类药物治疗的可能性较小(50.6%vs61.1%).那些使用更多数量的试样的人基本上不太可能改变和终止他汀类药物治疗。在1年时，优惠券用户的每月自付费用低于非优惠券用户（9.7美元对15.1美元），但每月总费用在质量上相似(115.5美元对116.9美元)。四年后，与非优惠券用户相比，优惠券用户的每月自付费用仍然较低(14.3美元对16.6美元)。敏感性分析支持主要结果。
品牌他汀类药物的优惠券与更高的利用率和更低的停药率以及短期转换为其他他汀类药物产品相关。
